Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Open-Label, Randomized, Single Dose and Repeat Dose Study to Evaluate the Single and Repeat Dose Safety and Tolerability of Intravitreally Administered PYC-001 in Participants With Confirmed OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy

NCT06970106 is registered in ClinicalTrials.gov with PYC Therapeutics as lead sponsor.

NCT NCT06970106
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06970106 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Open-Label, Randomized, Single Dose and Repeat Dose Study to Evaluate the Single and Repeat Dose Safety and Tolerability of Intravitreally Administered PYC-001 in Participants With Confirmed OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy
Lead sponsor
PYC Therapeutics
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 30, 2025
Completion date
November 30, 2029
Enrollment
24 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

autosomal dominant optic atrophy, hereditary optic atrophies, kjer optic atrophy, opa1 gene mutation